SignalRx Pharmaceuticals Inc. is a clinical stage company incorporated in Delaware in 2012, with operations in San Diego, California and Omaha, Nebraska. The company is focused on developing effective anticancer treatments inducing the immune system to attack cancer while blocking the most important and critical cell signaling pathways that cancer cells use to proliferate, migrate, metastasize, and recruit a blood supply.

Our efforts are aimed at combining the maximum anticancer activity into our drugs by selectively inhibiting as many important cancer targets as possible in a well-tolerated non-toxic manner where we also engage the immune system machinery to achieve maximum synergistic anticancer effects.

“There is no shortage of cancer treatments today either approved or in clinical development, the shortage is cancer treatments that significantly improve survival of cancer patients” said Dr. Don Durden, SignalRx founder.

Evolving Cancer Biology and Immuno-Oncology Create the Opportunity. Many intracellular kinase and immune checkpoint pathways are of interest for small-molecule therapy development since many biological targets in these pathways are cancer drivers. The founders of SignalRx are inventors of the second PI3K inhibitor to enter the clinic and are leaders capitalizing on selective multi-target single small-molecule drug design and development.

SignalRx is pursuing unique programs targeting the combined inhibition of key pathways involved in cancer proliferation, metastasis, angiogenesis as well as immuno-oncology (e.g., BTK, BRD4, CDK, PI3K, MYC).